3 Secret Strategies to Nabbing Your Dream Home
Accumulation Trumps Allocation in Your Retirement Portfolio
Does That Defrosting Tray Seen on TV Really Save Time?
The 3 Most Successful IPOs of 2014 (So Far)
Is Celgene the Perfect Stock?
Merck has confirmed that it halted its late-stage student of vorapaxar, a potential clot-preventing drug, after an increased risk of bleeding in some patients.